Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria

International Journal of Antimicrobial Agents

Volumn 35, Issue 6, 2010, Pages 553-558

  Nicolosi, Daria ^a   Scalia, Marina ^a   Nicolosi, Vito M ^a   Pignatello, Rosario ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Fusogenic liposomes; Gram negative bacteria; SEM; SUVET; TEM

Indexed keywords

CHOLESTEROL HYDROGEN SUCCINATE; DRUG CARRIER; LIPOSOME; PHOSPHOLIPID; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOPLASM; DRUG DISTRIBUTION; DRUG PENETRATION; ENCAPSULATION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ANTI-BACTERIAL AGENTS; DRUG CARRIERS; GRAM-NEGATIVE BACTERIA; HUMANS; LIPOSOMES; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; VANCOMYCIN;

EID: 77951766543     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.01.015     Document Type: Article

References (46)

1. Coates A.R., Hu Y. Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol 2007, 152:1147-1154.
2. Fenske D.B., Cullis P.R. Liposomal nanomedicines. Expert Opin Drug Deliv 2008, 5:25-44.
3. Yacoby I., Benhar I. Antibacterial nanomedicine. Nanomedicine 2008, 3:329-341.
4. Alipour M., Halwani M., Omri A., Suntres Z.E. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int J Pharm 2008, 355:293-298.
5. Goyal P., Goyal K., Vijaya Kumar S.G., Singh A., Katare O.P., Mishra D.N. Liposomal drug delivery systems-clinical applications. Acta Pharm 2005, 55:1-25.
6. Briones E., Colino I., Lanao J.M. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Control Release 2008, 125:210-227.
7. Carlone N.A., Cuffini A.M., Tullio V., Cavallo G. Interactions of antibiotics with phagocytes in vitro. J Chemother 1991, 3(Suppl. 1):98-104.
8. Gamazo C., Prior S., Concepción Lecároz M., Vitas A.I., Campanaro M.A., Pérez G., et al. Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections. Expert Opin Drug Deliv 2007, 4:677-688.
9. Pagès J.M., James C.E., Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 2008, 6:893-903.
10. James P.A., Reeves D.S. Bacterial resistance to cephalosporins as a function of outer membrane permeability and access to their target. J Chemother 1996, 8(Suppl. 2):37-47.
11. Hancock R.E.W. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative Gram-negative bacteria. Clin Infect Dis 1998, 27(Suppl. 1):S93-S99.
12. Hancock R.E.W., Brinkman F.S.L. Function of Pseudomonas porins in uptake and efflux. Annu Rev Microbiol 2002, 56:17-38.
13. Vila J., Martí S., Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007, 59:1210-1215.
14. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003, 51:1109-1117.
15. Vaara M. Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in Gram-negative enteric bacteria. Antimicrob Agents Chemother 1993, 37:354-356.
16. Quintiliani R., Courvalin P. Mechanisms of resistance to antimicrobial agents. Manual of clinical microbiology 1995, 1319. ASM Press, Washington, DC. 6th ed. P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken (Eds.).
17. Chang S., Sievert D.M., Hageman J.C., Boulton M.L., Tenover F.C., Downes F.P., et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003, 348:1342-1347.
18. Reynolds P.E., Courvalin P. Vancomycin resistance in enterococci due to synthesis of precursors terminating in d-alanyl-d-serine. Antimicrob Agents Chemother 2005, 49:21-25.
19. Duzgunes N., Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev 1999, 40:3-18.
20. Goryacheva Y.A., Vekshina O.M., Yashin V.A., Kim Y.A. Fusion and endocytosis of anionic liposomes with Ehrlich ascitic carcinoma cells. Bull Exp Biol Med 2005, 140:733-735.
21. Knoll G., Burger K.N., Bron R., van Meer G., Verkleij A.J. Fusion of liposomes with the plasma membrane of epithelial cells: fate of incorporated lipids as followed by freeze fracture and autoradiography of plastic sections. J Cell Biol 1988, 107:2511-2521.
22. Watabe A., Yamaguchi T., Kawanishi T., Uchida E., Eguchi A., Mizuguchi H., et al. Target-cell specificity of fusogenic liposomes: membrane fusion-mediated macromolecule delivery into human blood mononuclear cells. Biochim Biophys Acta 1999, 1416:339-348.
23. Dzau V.J., Mann M.J., Morishita R., Kaneda Y. Fusogenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996, 93:11421-11425.
24. Goto T., Morishita M., Nishimura K., Nakanishi M., Kato A., Ehara J., et al. Novel mucosal insulin delivery systems based on fusogenic liposomes. Pharm Res 2006, 23:384-391.
25. Kunisawa J., Nakagawa S., Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv Drug Deliv Rev 2001, 52:177-186.
26. Nakanishi M., Mizuguchi H., Ashihara K., Senda T., Eguchi A., Watabe A., et al. Gene delivery systems using the Sendai virus. Mol Membr Biol 1999, 16:123-127.
27. Boomer J.A., Qualls M.M., Inerowicz H.D., Haynes R.H., Patri V.S., Kim J.M., et al. Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate. Bioconjug Chem 2009, 20:47-59.
28. Karanth H., Murthy R.S pH-sensitive liposomes-principle and application in cancer therapy. J Pharm Pharmacol 2007, 59:469-483.
29. Sakaguchi N., Kojima C., Harada A., Koiwai K., Kono K. The correlation between fusion capability and transfection activity in hybrid complexes of lipoplexes and pH-sensitive liposomes. Biomaterials 2008, 29:4029-4036.
30. Templeton N.S. Nonviral delivery for genomic therapy of cancer. World J Surg 2009, 33:685-697.
31. Lasch J., Weissig V., Brandl M. Preparation of liposomes. Liposomes-a practical approach 2003, 3-30. Oxford University Press, Oxford, UK. 2nd ed. V.P. Torchilin, V. Weissig (Eds.).
32. Jehl F., Gallion C., Thierry R.C., Monteil H. Determination of vancomycin in human serum by high-pressure liquid chromatography. Antimicrob Agents Chemother 1985, 27:503-507.
33. Clinical Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100-S17 2007, CLSI, Wayne, PA.
34. Hope M.J., Nayar R., Mayer L.D., Cullis P.R. Reduction of liposome size and preparation of unilamellar vesicles by extrusion techniques. Liposome technology 1993, vol. 1:123-139. CRC Press, Boca Raton, FL. 2nd ed.
35. Beaulac C., Sachetelli S., Lagace J. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gram-negative and Gram-positive bacteria. J Antimicrob Chemother 1998, 41:35-41.
36. Guo X., Szoka F.C. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG-diortho ester-lipid conjugate. Bioconjug Chem 2001, 12:291-300.
37. Lubrich B., van Calker D., Peschka-Süss R. Inhibition of inositol uptake in astrocytes by antisense oligonucleotides delivered by pH-sensitive liposomes. Eur J Biochem 2001, 267:2432-2438.
38. Kono K., Iwamoto M., Nishikawa R., Yanagie H., Takagishi T. Design of fusogenic liposomes using a poly(ethylene glycol) derivative having amino groups. J Control Release 2000, 68:225-235.
39. Mok K.W., Cullis P.R. Structural and fusogenic properties of cationic liposomes in the presence of plasmid DNA. Biophys J 1997, 73:2534-2545.
40. Simões S., Slepushkin V., Düzgünes N., Pedroso de Lima M.C. On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta 2001, 1515:23-37.
41. Epand R.M., Fuller N.L., Rand R.P. Role of the position of unsaturation on the phase behavior and intrinsic curvature of phosphatidylethanolamines. Biophys J 1996, 71:1806-1810.
42. Abbo A., Carmeli Y., Navon-Venezia S., Siegman-Igra Y., Schwaber M.J. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007, 26:793-800.
43. Halwani M., Mugabe C., Azghani A.O., Lafrenie R.M., Kumar A., Omri A. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J Antimicrob Chemother 2007, 60:760-769.
44. Mugabe C., Halwani M., Azghani A.O., Lafrenie R.M., Omri A. Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006, 50:2016-2022.
45. Sachetelli S., Khalil H., Chen T., Beaulac C., Sénéchal S., Lagacé J. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim Biophys Acta 2000, 1463:254-266.
46. Albrecht M.C., Griffith M.E., Murray C.K., Chung K.K., Horvath E.E., Ward J.A., et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg 2006, 203:546-550.